NASDAQ:TSHA

Taysha Gene Therapies Stock Insider Trading

etoro logo Buy TSHA
*Your capital is at risk
$5.55
-0.140 (-2.46%)
At Close: Jun 03, 2026

Taysha Gene Therapies Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -30.37. In total, the insiders bought 17.87M and sold 1.85M TSHA shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power

(Last 100 transactions)
-30.37
Buy 17.87M shares
Sell 1.85M shares
80% Buy Activity
Strong Negative Correlation
Sell Signal Medium Confidence
Jan 23, 2026

Analysis Breakdown:

  • Supported by a negative Insider Power Score of -30.37.
  • Partially supported by a negative historical correlation.
  • Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date Type Person Role Amount
Jun 01, 2026
Buy
Stock Option (right to buy)
A-Award
Stalfort John A Iii
Director
Director 42 671
Value: $254.7K
Jun 01, 2026
Buy
Common Stock
A-Award
Stalfort John A Iii
Director
Director 21 335
Value: $127.4K
Jun 01, 2026
Buy
Common Stock
A-Award
Donenberg Phillip B.
Director
Director 21 335
Value: $127.4K
Jun 01, 2026
Buy
Stock Option (right to buy)
A-Award
Donenberg Phillip B.
Director
Director 42 671
Value: $254.7K
Jun 01, 2026
Buy
Common Stock
A-Award
Long Alison S
Director
Director 21 335
Value: $127.4K
Jun 01, 2026
Buy
Stock Option (right to buy)
A-Award
Long Alison S
Director
Director 42 671
Value: $254.7K
Jun 01, 2026
Buy
Common Stock
A-Award
Sepp-lorenzino Laura
Director
Director 21 335
Value: $127.4K
Jun 01, 2026
Buy
Stock Option (right to buy)
A-Award
Sepp-lorenzino Laura
Director
Director 42 671
Value: $254.7K
Apr 10, 2026
Buy
Employee Stock Option (right to buy)
M-Exempt
Nagendran Sukumar
President And Head Of R&d
CEO / President 19 021
Value: $32.5K
Apr 10, 2026
Sell
Common Stock
S-Sale
Nagendran Sukumar
President And Head Of R&d
CEO / President 200 000
Value: $892.0K
Apr 10, 2026
Buy
Common Stock
M-Exempt
Nagendran Sukumar
President And Head Of R&d
CEO / President 19 021
Value: $32.5K
Feb 04, 2026
Sell
Common Stock
S-Sale
Alam Kamran
Chief Financial Officer
C-Suite Officer 1 655
Value: $7K
Jan 26, 2026
Sell
Common Stock
S-Sale
Nagendran Sukumar
President And Head Of R&d
CEO / President 26 918
Value: $124.1K
Jan 26, 2026
Sell
Common Stock
S-Sale
Nolan Sean P.
Chief Executive Officer
CEO / President 41 312
Value: $190.4K
Jan 26, 2026
Sell
Common Stock
S-Sale
Alam Kamran
Chief Financial Officer
C-Suite Officer 23 849
Value: $109.9K
Jan 23, 2026
Sell
Common Stock
S-Sale
Nolan Sean P.
Chief Executive Officer
CEO / President 136 789
Value: $649.7K
Jan 23, 2026
Sell
Common Stock
S-Sale
Nagendran Sukumar
President And Head Of R&d
CEO / President 89 132
Value: $423.4K
Jan 23, 2026
Sell
Common Stock
S-Sale
Alam Kamran
Chief Financial Officer
C-Suite Officer 78 968
Value: $375.1K
Jan 12, 2026
Buy
Employee Stock Option (right to buy)
A-Award
Nagendran Sukumar
President And Head Of R&d
CEO / President 274 000
Value: $1.33M
Jan 12, 2026
Buy
Common Stock
M-Exempt
Nagendran Sukumar
President And Head Of R&d
CEO / President 111 324
Value: $77.8K
Jan 12, 2026
Buy
Common Stock
M-Exempt
Nagendran Sukumar
President And Head Of R&d
CEO / President 88 676
Value: $151.6K
Jan 12, 2026
Buy
Employee Stock Option (right to buy)
A-Award
Nolan Sean P.
Chief Executive Officer
CEO / President 648 000
Value: $3.15M
Jan 12, 2026
Buy
Common Stock
A-Award
Nolan Sean P.
Chief Executive Officer
CEO / President 1 008 000
Value: $4.90M
Jan 12, 2026
Buy
Common Stock
A-Award
Nagendran Sukumar
President And Head Of R&d
CEO / President 427 000
Value: $2.08M
Jan 12, 2026
Sell
Common Stock
S-Sale
Nagendran Sukumar
President And Head Of R&d
CEO / President 200 000
Value: $942.0K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

Click to get the best stock tips daily for free!
ABOUT TAYSHA GENE THERAPIES, INC.
Taysha Gene Therapies
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of ...
GOLDEN STAR
Ticker Change Signal Date
LITE
$905.00
3.65% Jun 01
RUN
$12.83
15.74% May 06
GLBE
$31.61
0.569% May 05
SAP
$172.39
4.80% May 05
ADBE
$243.57
5.20% Apr 29

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE